Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 10/20 | 0.63 |
| ▸ | GSK3B | P49841 | 7/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | GPR39 | O43194 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.41 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13289158 | 0.92 | CDK2 (0.63) | CDK2GSK3BMEN1KMT2ANPC1 | |
| SCHEMBL13304831 | 0.90 | CDK2 (0.58) | CDK2GSK3BMEN1KMT2ANPC1 | |
| SCHEMBL13305297 | 0.90 | CDK2 (0.77) | CDK2GSK3BMEN1KMT2ANPC1 | |
| SCHEMBL14043231 | 0.89 | GSK3B (0.50) | CDK2GSK3BMEN1KMT2ANPC1 | |
| SCHEMBL12953026 | 0.88 | CDK2 (0.81) | CDK2GSK3BCCNE1CCNA2CCNA1 | |
| SCHEMBL13305196 | 0.88 | CDK2 (0.63) | CDK2GSK3BMEN1KMT2ANPC1 | |
| SCHEMBL13305319 | 0.87 | CDK2 (0.60) | CDK2GSK3BMEN1KMT2ANPC1 | |
| SCHEMBL12953920 | 0.85 | CDK2 (0.60) | CDK2GSK3BMEN1KMT2ANPC1 | |
| SCHEMBL13305311 | 0.85 | GSK3B (0.79) | CDK2GSK3BCCNE1 | |
| SCHEMBL14545901 | 0.83 | CDK2 (0.55) | CDK2GSK3BMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537116-B1 | PYRAZOLOPYRIMIDINES SUITABLE FOR THE TREATMENT OF CANCER DISEASES | SCHERING CORP (US) | 2010-06-02 | — | — | EP | disclosed |